EOC Pharma, an oncology-focused biopharmaceutical company, on Monday announced that it has secured nearly 500 million yuan ($71 million) in a Series C round of financing led by Tigermed, TF Capital, and Yingke PE.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
